The Citizens Commission on Human Rights International is alerting consumers that marketing of psychedelics as “plant-based” or “natural” remedies is misleading. Substances including ibogaine, psilocybin, and MDMA are actually synthetic, lab-produced chemicals carrying serious risks. The caution follows an Executive Order signed on April 18, 2026 that orders acceleration of research, regulatory review, and access to psychedelic compounds for serious mental health issues.
While active molecules like psilocybin occur naturally in plants or fungi, pharmaceutical versions are chemically synthesized under Good Manufacturing Practice standards. LSD, for example, is produced through complex lab processes rather than direct plant extraction. Despite this synthetic nature, investor projections for the “Botanical and Plant Derived Drugs Market” have surged to an anticipated $79.74 billion by 2031, dramatically higher than pre-order psychedelic market forecasts of $8.75 billion by 2031.
The organization points to growing evidence of serious adverse effects from psychedelics. Real-world incidents cited include a UK artist who died by suicide after consuming hallucinogenic “tea” at a retreat, with a coroner linking deterioration to the substance. An off-duty pilot ingested psilocybin mushrooms 48 hours before a flight and attempted to shut off engines mid-flight, endangering 83 people. In 2023, a U.S. Army Specialist consumed psilocybin at a music festival and subsequently shot and killed two people and wounded three others while hallucinating.
Psychedelic treatments positioned as drug-assisted psychotherapy in controlled clinical settings face significant economic and practical challenges. Estimated MDMA-assisted PTSD therapy costs $7,543 per patient, with Australian costs reaching $20,000 for sessions and counseling. Ketamine clinics demonstrate profitability, with vials costing about $40 wholesale but billed at $1,000 or more per treatment. More than 1,000 U.S. ketamine clinics operate off-label, with psychiatrist salaries in Los Angeles averaging $353,165. The broader ketamine market generated $3.1 billion in 2022, with more than 80 companies now developing psychedelic compounds, fueled by venture capital and declining antidepressant revenues.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/prlog-2026-5-5-cchr-plant-based-psychedelics-push-masks-synthetic-drugs-and-billion-dollar-profits